Exploring Statin Intolerance

Slides:



Advertisements
Similar presentations
The Latest Lipid Guidelines:
Advertisements

PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Updates and Perspectives in Diabetic Dyslipidemia
PCSK9 Inhibitors Post-CVOTs
New Guidelines to Prevent SCD: What You Need to Know
Statin Selection in the Elderly
Optimizing Statin Therapy
Omega-3 Prescriptions vs Supplements in Practice
Challenging Statin Intolerance: Back to Basics
Modern Strategies for Basal Insulin Use in T2D
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Patient 1: 53-Year-Old Man With CVD Risk Factors
Select Topics in Cardiovascular Medicine
Statins and the Elderly Patient
Statin Selection in Special Patient Populations: A Case Challenge
What Do We Know About LDL-C?
Understanding Statin Metabolism
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
Heart Failure Prevention: Mission Impossible?
Diabetes Increases Risk of CVD
An Update on PCSK9 Inhibitors
Talking to Patients About Diabetes Management
Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.
A Pharmacist's Guide to PCSK9 Inhibitors:
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
What's New in Dyslipidemia?
Statins and Glucose Metabolism: Are All Agents Alike?
PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins
Personalizing Statin Therapy in Patients With HIV
A Journal Club on Lipid Management:
PCSK9 Inhibitors and Cardiovascular Outcomes
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Improving Appropriate Access to PCSK9 Inhibitors
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
Statins and HIV:.
New LDL-C Lipid Targets
A PCP's Guide to Dyslipidemia
Radical New Concepts in Lipid Management
Atrial Fibrillation.
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
Aspirin and Cardioprevention in 2018
Clinicians' Corner in Dyslipidemia
Program Goals Overview Is NEDA a Reasonable Target?
Residual CV Risk in Patients With Dyslipidemia and Stable CAD
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Monoclonal Antibodies in CVD: What Does the Future Hold?
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.
Statins, Obesity, and Hyperlipidemia
Glucose Management and Statin Therapy
How to Optimize Cholesterol Management in High-Risk CV Patients
Latest Lipid Guidelines in Perspective
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Improving Effective Basal Insulin Use in Clinical Practice
Improving Adherence to Antiplatelet Therapy After an ACS Event
New Lipid-Lowering Guidelines
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
Statins and Glucose Metabolism: An Endocrinology Perspective
Addressing Cardiovascular Events:
Glucose Management and Statin Therapy
PCSK9 Inhibitors and Statin Intolerance
Updates on Dyslipidemia
Evaluating the Science of Cardiogenic Shock
Key Data on Improving Outcomes in HF Patients
PCSK9 Inhibitors and Real-World Evidence
Shared-Decision Making in Dyslipidemia
Presentation transcript:

Exploring Statin Intolerance

Incidence/Prevalence of Statin Intolerance

Statin AEs

High Risk Patients and Statin Intolerance

Statins, ASCVD, VA Hospitals

Pattern of Statin Use After Discharge for MI

Statin Intolerance

Key Points About SAMS for Clinicians

Who Is at Risk?

What Determines Management of SAMS?

AEs: Perception vs Evidence Glucose homeostasis -- Clinical Update ESC 2018

Benefits of Statins Far Outweigh Risks

NLA on Statin Intolerance

Spectrum of SAMS Events

Ask About Change in Activity

Strategies to Address Intolerance

Cardiovascular Team-Based Care and the Role of Advanced Practice Providers

Statin Pharmacokinetics

Statins High/Medium/Low

Ethnic Differences in Statin Metabolism

Strategies to Address Intolerance

Exhaust the Statin Class Before Giving Up

NLA Recommendations Consistent With Those Found in the ACC's Tool

The Takeaway

Keep Trying Benefits Outweighs Risks!

Abbreviations

Abbreviations (cont)